12th ANNUAL EUROPEAN LIFE SCIENCES CEO FORUM

Back for its 12th Annual edition, this global bio-pharma industry forum addresses through its conference programme the main challenges for 2019 in investment, partnering and alliance management.
sachs forum 2019
The forum also features keynote speeches by KOL and about 60 selected corporate presentations from established (public and private) and emerging biotechs seeking to promote investment and partnering opportunities. We expect over 350 delegates to attend the event. The forum will provide a number of networking opportunities via our online one-to-one meeting system which allows you to pre-book meetings with all the attendees at the dedicated meeting facilities. We anticipate more than 1500 face-to-face meetings to take place throughout 2 days.

This year, following our conference, in the afternoon of the 26th they will also host the 1st GoforIsrael Life Sciences Conference. They will bring together leading global investors and Israel’s best opportunities from the Life Sciences industry, addressing current issues related to raising capital and establishing strategic alliances in Europe.
Plenary Sessions include:

  • China-Europe Partnering & Investment Panel
  • Early Stage Investor Roundtable
  • “Latest Trends in Fund Raising & Investment” – Private Equity & VC Panel
  • Pharma DealMakers Roundtable
  • “Prospects for 2019”- Global Biopharma Industry Review Panel
  • Rising Stars: Start-Up Showcase

Therapeutic Panels include:

  • Advances in C&G Therapies Panel
  • Autoimmune & Inflammatory Diseases Panel
  • Neuroscience BD&L Panel
  • Platform Technologies & Novel Therapeutics Panel
  • Oncology Advanced Therapies and Diagnostics Panel
  • Oncology DealMaking Panel

Confirmed Keynotes include:

  • Søren Bjønness, Director – Switzerland Representative, Euronext

Confirmed Speakers & Chairs include:

  • Alain Vertès, Managing Director, NxR Biotechnologies GmbH
  • Anja König, Managing Director, Novartis Venture Fund
  • Annegret de Baey, Venture Partner Life Sciences Department, Seventure Partners
  • Bernd Goergen, Partner, High-Tech-Gruenderfonds Management GmbH
  • Bibhash Mukhopadhyay, Principal, New Enterprise Associates, Inc.
  • Bruce Steel, President & CBO, Equillium, Inc.
  • Carlos Buesa Arjol, Chief Executive Officer, Oryzon Genomics S.A.
  • Constantine Chinoporos, CBO, Boston Pharmaceuticals
  • Dirk Beher, CEO, Asceneuron SA
  • David Horn Solomon, CEO, Silence Therapeutics Plc.
  • Dragan Grabulovski, CEO & Founder, Grabulovski Consulting Services
  • Echo Hindle-Yang, CEO & Founder, MSQ Ventures
  • Eric Halioua, President & Chief Executive Officer, PDC*line Pharma SA
  • Esteban Pombo Villar, CEO, TargImmune Therapeutics AG
  • Eugene Williams, Executive Chairman, ProMIS™ Neurosciences, Inc.
  • Fintan Walton, CEO, PharmaVentures Ltd.
  • Francesco de Rubertis, Partner, Medicxi
  • François Thomas, Venture Partner, Sofimac Innovation
  • Gil Bar-Nahum, Managing Director, Jefferies Group LLC
  • Grace Colon, CEO, InCarda Therapeutics, Inc.
  • Guillaume Vignon, SVP Business Development, BeiGene GmbH
  • Hartmut Ehrlich, CEO, ABIVAX
  • Heinz Lubenau, Chief Operating Officer, VAXIMM GmbH
  • Holger Reithinger, General Partner, Forbion Capital Partners
  • Jonathan Tobin, Investment Director, Arix Bioscience Plc.
  • Jörg Neermann, Partner, LSP
  • Karl Nägler, Partner, Gimv
  • Katya Smirnyagina, Partner, Capricorn Venture Partners NV
  • Keno Gutierrez, Investment Director, Healthcare, M Ventures
  • Kevin Pan, Co-Founder, Chairman & CEO, Asieris Pharmaceuticals
  • Lars Gredsted, Associate Director, Partnering & Strategy, MedImmune, LLC
  • Lubor Gaal, SVP, Head of Europe, Locust Walk
  • Lynn Durham, Founder & CEO, Stalicla SA
  • Margarita Chavez, Managing Director, AbbVie Ventures
  • Markus Hosang, General Partner, BioMedPartners AG
  • Markus Kalousek, Head of Pharma Search & Evaluation, Global BD&L, Novartis Pharma AG
  • Martin Olin, CEO, Symphogen A/S
  • Martin Welschof, CEO, BioInvent International AB
  • Mathieu Bigois, Venture Partner and Head of Europe, Ally Bridge Group
  • Matthias Müllenbeck, Director Global Oncology L&BD, Global BD & Alliance Management, Merck KGaA
  • Michael Altorfer, CEO, Swiss Biotech Association
  • Michael Huebner, BD&L Manager, Roche Partnering Oncology, F.Hoffmann-La Roche Ltd.
  • Michel Baijot, CEO, ASIT Biotech
  • Michel Wurm, VP, Medical Affairs, Strategy & BD, Pharmaleads SA
  • Mirko Scherer, Managing Partner, TVM Capital China Ltd.
  • Morten Graugaard Døssing, Principal, Novo Holdings A/S
  • Nathalie ter Wengel, European Head External R&D and Innovation, Pfizer, Inc.
  • Nicholas Franco, EVP & CBDO, Actelion, a Janssen Pharmaceuticals Company of Johnson & Johnson
  • Nigel Sheail, Head of Global Business Development & Licensing, Novartis Pharma AG
  • Olav Hellebo, CEO, ReNeuron Group Plc.
  • Olivier Litzka, Partner, ANDERA PARTNERS
  • Olivier Reinhard, Global Head of BD & Licensing, General Medicines and Emerging Markets, Sanofi
  • Patrick Benz, Senior Director Alliance Management, the Janssen Pharmaceutical Companies of Johnson & Johnson
  • Peter Pack, CEO , Crescendo Biologics Ltd.
  • Pierre Vandepapelière, CEO & CMO, Imcyse SA
  • Rainer Strohmenger, General Partner, Wellington Partners
  • Roby Zomer, CEO & Executive Director, MGC Pharmaceuticals Ltd.
  • Ruth Devenyns, CEO, Camel-IDS NV/SA
  • Sarah Holland, Head of Licensing, Pharma and Biotech, Lonza AG
  • Simon Blake, Senior Director, Scientific Licensing, the Janssen Pharmaceutical Companies of Johnson & Johnson
  • Simone Botti, CEO, Metabomed Ltd.
  • Stephan Lensky, COO & CBO, EpimAb Biotherapeutics, Inc.
  • Stephanie Léouzon, Partner and Head of Torreya Partners Europe, Torreya Partners (Europe) LLP
  • Stewart Kay, Director, Business Development, GlaxoSmithKline
  • Susanne Wiegel, Senior Director BD & Portfolio Management, MorphoSys AG
  • Tim Haines, Managing Partner, Abingworth LLP
  • Timothy Luker, VP, Emerging Technology & Innovation, BD, Eli Lilly and Company
  • Torsten Mummenbrauer, Senior Vice President Business Development, Management, Hookipa Biotech GmbH
  • Wolfgang Brysch, Founder and Chief Executive Officer, MetrioPharm AG
  • Yochi Slonim, Co-Founder, CEO, Anima Biotech, Inc.
  • ZhiZhong Joel Yao, Associate, Sofinnova Partners SA
  • And more TBA…